Exploring the mechanisms underlying the analgesic effect of Cannabidiol using Proton Magnetic Resonance Spectroscopy.

使用质子磁共振波谱探索大麻二酚镇痛作用的机制。

基本信息

  • 批准号:
    9893763
  • 负责人:
  • 金额:
    $ 15.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-15 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract: Chronic pain is a prevalent disorder affecting approximately 100 million Americans. Treatment of chronic pain has heavily relied on opioid drugs, however; the use of opioids is accompanied with significant shortcomings including lack of efficacy in the long term and the risk for dependence that has contributed significantly to the national opioid epidemic. Thus, development and identification of novel strategies for pain management in chronic pain is a critical unmet need. A burgeoning body of literature suggests that the Cannabis plant has analgesic properties, with reported therapeutic effects ranging from substantial to conclusive in both preclinical and clinical studies. The main psychoactive constituent in the cannabis plant, tetrahydrocannabinol (THC) has demonstrated analgesic effects, however; its use is limited by adverse psychoactive and cognitive effects. However, not all isomers of THC demonstrate psychoactive effects. For example, cannabidiol (CBD) has been shown to demonstrate analgesic properties without psychoactive effects. The biological mechanisms underlying the analgesic efficacy of CBD are relatively unexplored and hence mechanistic studies investigating this research question are needed. CBD has a complex pharmacology with agonist and antagonist activity at several receptors including but not limited to endocannabinoid CB1 and CB2 receptors, serotonin 5-HT1A receptors, gamma-amino butyric acid receptors (GABA-A), and vanilloid receptors. In addition, CBD is a potent anti-inflammatory and has shown to decrease levels of cytokines and other pro-inflammatory signaling molecules. The goal of the proposed study, which responds to RFA-AT-19-009, is to evaluate changes in brain chemistry after a short-term (5-day) administration of a cannabis extract enriched in CBD using proton magnetic resonance spectroscopy (1H-MRS). 1H-MRS allows the measurement of in vivo levels of brain metabolites such as N-acetylaspartate, creatine, lactate, glutamate, GABA, glutamine (Gln), and myoinositol (mI). MRS studies of chronic pain have demonstrated changes in glutamate and GABA signaling in critical pain-processing regions of the brain. Furthermore, chronic pain has also been associated with increased levels of pro-inflammatory signaling molecules. Thus, pharmacological agents that can modulate central glutamate and GABAergic tone may exhibit potent analgesic activity. With the proposed study, we aim to investigate whether a short-term administration of a cannabis extract enriched in CBD can modulate glutamate and GABAergic signaling in critical pain-processing regions of the brain such as the anterior cingulate cortex (ACC) and insula. Furthermore, we plan to investigate the effects of CBD on peripheral and neural markers of inflammation. The successful completion of the study will advance the evidence-based application of CBD as a potential treatment for pain conditions and will also provide substrates that can be targeted to reduce neuroinflammation.
项目摘要/摘要:慢性疼痛是影响大约1亿美国人的一种普遍疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PERRY FRANKLIN RENSHAW其他文献

PERRY FRANKLIN RENSHAW的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PERRY FRANKLIN RENSHAW', 18)}}的其他基金

Exploring the mechanisms underlying the analgesic effect of Cannabidiol using Proton Magnetic Resonance Spectroscopy.
使用质子磁共振波谱探索大麻二酚镇痛作用的机制。
  • 批准号:
    10017872
  • 财政年份:
    2019
  • 资助金额:
    $ 15.25万
  • 项目类别:
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
女性甲基苯丙胺使用者肌酸的随机双盲对照试验
  • 批准号:
    9250944
  • 财政年份:
    2017
  • 资助金额:
    $ 15.25万
  • 项目类别:
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
女性甲基苯丙胺使用者肌酸的随机双盲对照试验
  • 批准号:
    10227185
  • 财政年份:
    2017
  • 资助金额:
    $ 15.25万
  • 项目类别:
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
女性甲基苯丙胺使用者肌酸的随机双盲对照试验
  • 批准号:
    9982831
  • 财政年份:
    2017
  • 资助金额:
    $ 15.25万
  • 项目类别:
Improving Therapeutic Options for Hypoxia-related Depression with an Animal Model
通过动物模型改善缺氧相关抑郁症的治疗选择
  • 批准号:
    9519716
  • 财政年份:
    2016
  • 资助金额:
    $ 15.25万
  • 项目类别:
Improving Therapeutic Options for Hypoxia-related Depression with an Animal Model
通过动物模型改善缺氧相关抑郁症的治疗选择
  • 批准号:
    9206094
  • 财政年份:
    2016
  • 资助金额:
    $ 15.25万
  • 项目类别:
1/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT U UTAH
1/21 ABCD-美国联盟:犹他大学研究项目现场
  • 批准号:
    10380162
  • 财政年份:
    2015
  • 资助金额:
    $ 15.25万
  • 项目类别:
1/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT U UTAH
1/21 ABCD-美国联盟:犹他大学研究项目现场
  • 批准号:
    9982699
  • 财政年份:
    2015
  • 资助金额:
    $ 15.25万
  • 项目类别:
Prospective Research Studies of Maturation (PRISM)- Research Project
成熟的前瞻性研究(PRISM)- 研究项目
  • 批准号:
    9280917
  • 财政年份:
    2015
  • 资助金额:
    $ 15.25万
  • 项目类别:
Prospective Research Studies of Maturation (PRISM)- Research Project
成熟的前瞻性研究(PRISM)- 研究项目
  • 批准号:
    9054569
  • 财政年份:
    2015
  • 资助金额:
    $ 15.25万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 15.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 15.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了